Most Read

The initial recommended prophylactic regimen for Jivi is twice weekly with the ability to dose every five days and further individually adjust to less or more frequent dosing

AstraZeneca, along with its global biologics research and development arm MedImmune, has reported the top-line results from the Tulip 1 phase III trial for anifrolumab in adult patients

The Phase 2 study (B5161002), did not meet its primary efficacy endpoint, which was to demonstrate a difference in the mean change from baseline in 4 Stair Climb

Onvansertib is a first-in-class, third generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor. Trovagene executive chairman Dr Thomas Adams said: “The European Commission’s decision to grant orphan

Under the terms of the agreement, Purdue will pay Assertio a total of $62 million in cash, with $30 million in cash paid on August 28, 2018 and

Harbour BioMed is engaged in the discovery and development of therapeutics for oncology and immunological diseases. The financing round was led by GIC Private Limited, and participants included

The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory,

The company will invest a double-digit million-euro figure to add another 50 percent to its existing capacity. The new production lines will be installed at the company’s syringe

The global partnership, which will exclude the Greater China region, is expected to fetch more than $350m to Kelun-Biotech in addition to royalties based on annual net sales.